HRP20171962T1 - L-ornitin fenilacetat i metode za njegovu pripremu - Google Patents

L-ornitin fenilacetat i metode za njegovu pripremu Download PDF

Info

Publication number
HRP20171962T1
HRP20171962T1 HRP20171962TT HRP20171962T HRP20171962T1 HR P20171962 T1 HRP20171962 T1 HR P20171962T1 HR P20171962T T HRP20171962T T HR P20171962TT HR P20171962 T HRP20171962 T HR P20171962T HR P20171962 T1 HRP20171962 T1 HR P20171962T1
Authority
HR
Croatia
Prior art keywords
preparation according
preparation
crystalline form
weight
ppm silver
Prior art date
Application number
HRP20171962TT
Other languages
English (en)
Croatian (hr)
Inventor
Keith Anderson
Jim Behling
Christine Henderson Dougen
Stephen William Watt
Peter Manini
Attilia Figini
Original Assignee
Ocera Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics, Inc. filed Critical Ocera Therapeutics, Inc.
Publication of HRP20171962T1 publication Critical patent/HRP20171962T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20171962TT 2009-04-03 2010-04-01 L-ornitin fenilacetat i metode za njegovu pripremu HRP20171962T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16667609P 2009-04-03 2009-04-03
EP10759442.6A EP2413924B1 (en) 2009-04-03 2010-04-01 L-ornithine phenyl acetate and methods of making thereof
PCT/US2010/029708 WO2010115055A1 (en) 2009-04-03 2010-04-01 L-ornithine phenyl acetate and methods of making thereof

Publications (1)

Publication Number Publication Date
HRP20171962T1 true HRP20171962T1 (hr) 2018-02-09

Family

ID=42828717

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20221232TT HRP20221232T8 (hr) 2009-04-03 2010-04-01 L-ornitin fenil acetat i postupci njegove pripreme
HRP20171962TT HRP20171962T1 (hr) 2009-04-03 2010-04-01 L-ornitin fenilacetat i metode za njegovu pripremu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20221232TT HRP20221232T8 (hr) 2009-04-03 2010-04-01 L-ornitin fenil acetat i postupci njegove pripreme

Country Status (26)

Country Link
US (9) US8173706B2 (enExample)
EP (4) EP3686183B1 (enExample)
JP (6) JP6144488B2 (enExample)
KR (6) KR102123243B1 (enExample)
CN (3) CN106810464B (enExample)
AU (1) AU2010232521B2 (enExample)
BR (1) BRPI1013657A2 (enExample)
CA (5) CA3077846C (enExample)
CY (1) CY1119843T1 (enExample)
DK (3) DK2413924T3 (enExample)
EA (2) EA023051B1 (enExample)
ES (3) ES2791524T3 (enExample)
HR (2) HRP20221232T8 (enExample)
HU (2) HUE060371T2 (enExample)
IL (2) IL215449B (enExample)
LT (2) LT3686183T (enExample)
MX (4) MX356608B (enExample)
NO (1) NO2413924T3 (enExample)
NZ (3) NZ619235A (enExample)
PL (2) PL2413924T3 (enExample)
PT (2) PT2413924T (enExample)
SG (3) SG10201406300YA (enExample)
SI (1) SI2413924T1 (enExample)
SM (2) SMT202200395T1 (enExample)
WO (1) WO2010115055A1 (enExample)
ZA (1) ZA201107189B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341120T3 (es) 2004-11-26 2010-06-15 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatia hepatica.
EA023051B1 (ru) 2009-04-03 2016-04-29 Осера Терапьютикс, Инк. Кристаллические формы фенилацетата l-орнитина и их применение
EA025735B1 (ru) 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
US8068011B1 (en) 2010-08-27 2011-11-29 Q Street, LLC System and method for interactive user-directed interfacing between handheld devices and RFID media
ES2720148T3 (es) 2010-10-06 2019-07-18 Ocera Therapeutics Inc Métodos de fabricación de fenilacetato de L-ornitina
CN102993037B (zh) * 2012-11-20 2015-03-04 南京工业大学 一种l-鸟氨酸苯乙酸盐的制备方法
CN105481725B (zh) * 2014-09-18 2019-01-22 博瑞生物医药（苏州）股份有限公司 L-精氨酸苯乙酸盐的晶型及其制备方法
DK3223829T3 (da) 2014-11-24 2020-02-10 Ucl Business Ltd Behandling af sygdomme associeret med hepatisk stellat-celleaktivering under anvendelse af ammoniak-sænkende terapier
EP3285756B1 (en) 2015-04-20 2023-02-22 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
US20200206174A1 (en) * 2015-09-25 2020-07-02 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
RU2018113801A (ru) * 2015-11-13 2019-12-16 Осера Терапьютикс, Инк. Составы l-орнитин фенилацетата
US11219611B2 (en) * 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP7126520B2 (ja) * 2017-05-11 2022-08-26 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンフェニルアセテートを製造する方法
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
CA3138914A1 (en) 2019-05-09 2020-11-12 Ocera Therapeutics, Inc. Methods of assessing and treating hepatic encephalopathy
CN110707221B (zh) * 2019-09-25 2023-09-01 北京大学深圳研究生院 氨基酸离子液体在制备钙钛矿光电器件中钙钛矿层的应用
CN114786662A (zh) * 2019-10-16 2022-07-22 欧塞拉治疗有限公司 鸟氨酸苯乙酸盐用于治疗高氨血症的剂量和用途
WO2023240081A1 (en) * 2022-06-06 2023-12-14 Yale University Treatment, amelioration, and/or prevention of inflammatory and autoimmune diseases
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (enExample) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4100161A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US3950529A (en) * 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4352814A (en) * 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) * 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
JP2522034B2 (ja) * 1988-12-27 1996-08-07 味の素株式会社 α−ケト酸・アミノ酸塩化合物及びその製造方法
JPH03273578A (ja) 1990-03-23 1991-12-04 Ricoh Co Ltd 対物レンズクリーニング装置
DE4020980C1 (enExample) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5560490A (en) 1992-09-09 1996-10-01 Fisons Plc Pharmaceutical packaging with capsule sealing means
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5840891A (en) * 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
WO1997030167A1 (en) 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) * 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
CA2374273A1 (en) 1999-05-21 2000-11-30 Takeda Chemical Industries, Ltd. Liver function controlling agents
US6768024B1 (en) * 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
DE60233558D1 (de) 2001-03-15 2009-10-15 Takashi Abe Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
US6503530B1 (en) * 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
WO2004019928A1 (ja) 2002-08-30 2004-03-11 Ajinomoto Co., Inc. 肝疾患治療剤
US20050059150A1 (en) * 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) * 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
AU2005216251B2 (en) * 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005108339A2 (en) * 2004-05-06 2005-11-17 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
JP2008511611A (ja) * 2004-08-30 2008-04-17 ルナメツド・インコーポレーテツド 治療用４−フェニル酪酸制御放出製剤
ES2341120T3 (es) 2004-11-26 2010-06-15 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatia hepatica.
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
ME01879B (me) 2005-11-17 2014-12-20 Stabilna formulacija amorfnih perindopril soli, postupak njihove pripreme, posebno industrijske proizvodnje i njihova upotreba u terapiji hipertenzije
EA023051B1 (ru) * 2009-04-03 2016-04-29 Осера Терапьютикс, Инк. Кристаллические формы фенилацетата l-орнитина и их применение
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
EA025735B1 (ru) 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
JP2011236160A (ja) 2010-05-11 2011-11-24 Shinshu Univ 非アルコール性肝疾患治療薬
ES2720148T3 (es) 2010-10-06 2019-07-18 Ocera Therapeutics Inc Métodos de fabricación de fenilacetato de L-ornitina
HK1210699A1 (en) 2012-11-21 2016-05-06 Horizon Therapeutics, Inc. Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
DK3223829T3 (da) 2014-11-24 2020-02-10 Ucl Business Ltd Behandling af sygdomme associeret med hepatisk stellat-celleaktivering under anvendelse af ammoniak-sænkende terapier
EP3285756B1 (en) 2015-04-20 2023-02-22 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE

Also Published As

Publication number Publication date
EP2413924B1 (en) 2017-09-27
DK3263100T3 (da) 2020-05-11
EP3263100A1 (en) 2018-01-03
PT3686183T (pt) 2022-10-03
PL2413924T3 (pl) 2018-02-28
KR102217081B1 (ko) 2021-02-18
US8173706B2 (en) 2012-05-08
EP4101838A1 (en) 2022-12-14
CA3205755A1 (en) 2010-10-07
US8785498B2 (en) 2014-07-22
LT3686183T (lt) 2022-11-10
US20200239406A1 (en) 2020-07-30
EA034409B1 (ru) 2020-02-05
SMT202200395T1 (it) 2022-11-18
IL215449B (en) 2019-01-31
US20220162155A1 (en) 2022-05-26
KR102399540B1 (ko) 2022-05-17
SI2413924T1 (en) 2018-01-31
KR102123243B1 (ko) 2020-06-17
NZ595706A (en) 2014-01-31
EP2413924A4 (en) 2013-01-02
CA2998344A1 (en) 2010-10-07
MX2011010262A (es) 2012-01-25
US20120208885A1 (en) 2012-08-16
JP6010154B2 (ja) 2016-10-19
HUE035921T2 (en) 2018-05-28
JP2022088504A (ja) 2022-06-14
SG10202010988WA (en) 2020-12-30
KR20120006039A (ko) 2012-01-17
CA2998434C (en) 2020-05-12
KR20210019592A (ko) 2021-02-22
LT2413924T (lt) 2018-02-12
JP6328737B2 (ja) 2018-05-23
HUE060371T2 (hu) 2023-02-28
US20140288327A1 (en) 2014-09-25
NO2413924T3 (enExample) 2018-02-24
ES2652187T3 (es) 2018-01-31
JP6647336B2 (ja) 2020-02-14
BRPI1013657A2 (pt) 2016-04-26
DK3686183T3 (da) 2022-10-03
JP2017081940A (ja) 2017-05-18
US20100280119A1 (en) 2010-11-04
EP2413924A1 (en) 2012-02-08
HRP20221232T8 (hr) 2023-02-03
NZ708458A (en) 2017-02-24
EA201171216A1 (ru) 2012-05-30
SG10201406300YA (en) 2015-01-29
ZA201107189B (en) 2012-12-27
ES2791524T3 (es) 2020-11-04
CN104230730A (zh) 2014-12-24
US9034925B2 (en) 2015-05-19
CN106810464B (zh) 2019-01-22
CA2757373C (en) 2018-05-08
CA3077846A1 (en) 2010-10-07
IL263784A (en) 2019-01-31
US11161802B2 (en) 2021-11-02
CN102421432B (zh) 2014-09-17
KR101975726B1 (ko) 2019-05-07
JP2012522803A (ja) 2012-09-27
HK1248558A1 (en) 2018-10-19
EP3686183B1 (en) 2022-08-03
AU2010232521B2 (en) 2015-07-16
MX375111B (es) 2025-03-06
IL215449A0 (en) 2011-12-29
MX388894B (es) 2025-03-20
US10173964B2 (en) 2019-01-08
DK2413924T3 (en) 2017-12-11
US20180044281A1 (en) 2018-02-15
CA2998344C (en) 2020-06-02
US20130296429A1 (en) 2013-11-07
PT2413924T (pt) 2018-01-04
US10550069B2 (en) 2020-02-04
JP6144488B2 (ja) 2017-06-07
NZ619235A (en) 2015-06-26
CN102421432A (zh) 2012-04-18
EA201500650A1 (ru) 2015-10-30
ES2928586T3 (es) 2022-11-21
AU2010232521A1 (en) 2011-11-17
US20180319736A1 (en) 2018-11-08
KR101844605B1 (ko) 2018-04-02
WO2010115055A1 (en) 2010-10-07
EP3686183A1 (en) 2020-07-29
MX2020009699A (es) 2021-12-17
CA2757373A1 (en) 2010-10-07
JP2020100624A (ja) 2020-07-02
CY1119843T1 (el) 2018-06-27
US20150251990A1 (en) 2015-09-10
CA2998434A1 (en) 2010-10-07
HRP20221232T1 (hr) 2022-12-23
EP3263100B1 (en) 2020-04-01
CA3077846C (en) 2023-08-22
JP2015145372A (ja) 2015-08-13
JP7086118B2 (ja) 2022-06-17
JP2018138575A (ja) 2018-09-06
CN104230730B (zh) 2017-05-24
KR20180033313A (ko) 2018-04-02
SMT201700601T1 (it) 2018-03-08
EA023051B1 (ru) 2016-04-29
SG174982A1 (en) 2011-11-28
US8492439B2 (en) 2013-07-23
KR20220067001A (ko) 2022-05-24
US9604909B2 (en) 2017-03-28
KR20190068561A (ko) 2019-06-18
MX356608B (es) 2018-06-06
CN106810464A (zh) 2017-06-09
KR20200070438A (ko) 2020-06-17
PL3686183T3 (pl) 2022-11-28

Similar Documents

Publication Publication Date Title
HRP20171962T1 (hr) L-ornitin fenilacetat i metode za njegovu pripremu
FI2882444T3 (fi) Mikrohuokoinen zirkoniumsilikaatti hyperkalemian hoitoon
HRP20220182T1 (hr) Kristalni oblici inhibitora prolil hidroksilaze
HRP20230081T1 (hr) Kristalni monohidratni kompleks od 1-cijano-2-(4-ciklopropil-benzil)-4-(beta-d-glukopiranoz-1-il)-benzena i l- prolina u kristalnoj vodi (1:1:1), postupci za njegovu pripravu i njegova uporaba kao sglt inhibitora
BR112014003376A2 (pt) uso da liga de cobre
MX338382B (es) Composicion de gel.
BR112013003087A2 (pt) forma cristalina de composto de pirimidio[6,1-a]-isoquinolin-4-ona
NZ599377A (en) Salts, aqueous liquid compositions containing salts of S-(+)-abscisic acid and methods of their preparation
NZ598068A (en) High-strength, low viscosity herbicidal concentrate of clopyralid dimethylamine
EP2151241A4 (en) STABLE SOLID PREPARATION WITH 4,5-EPOXYMORPHINANE DERIVATIVE
HRP20171252T1 (hr) Kompozicija za oblaganje papirnatog omotača proizvoda za pušenje
MX364735B (es) Concentrado en suspensión acuosa que comprende una sal ácida de dodecilguanidina.
HRP20220626T1 (hr) Otopine bimatoprosta i timolola bez konzervansa
GB201307548D0 (en) Agrochemical compositions for reducing agrochemical residues
MX2013006824A (es) Cubo de esencia.
TN2011000597A1 (en) Non-caking salt composition, preparation process and use thereof
BR112014014440A2 (pt) aleta de liga de alumínio e método de fazer as mesmas
RU2014143772A (ru) Гербицидная композиция
Zafarani-Moattar et al. Apparent molar volumes, apparent isentropic compressibilities, and viscosity B-coefficients of 1-ethyl-3-methylimidazolium bromide in aqueous di-potassium hydrogen phosphate and potassium di-hydrogen phosphate solutions at T=(298.15, 303.15, 308.15, 313.15, and 318.15) K
FR2985511B1 (fr) Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
MX388315B (es) Formulacion activa para usarse en productos alimenticios.
IN2014KN01255A (en) Methods and compositions for the treatment of diverticulosis
TW200730498A (en) Compounds
MY157631A (en) Liquid cleaning compositions containing sulfonated estolides and alkyl ester sulfonates
RU2014153494A (ru) Состав для ухода за полостью рта